Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations

TUESDAY, Dec. 22, 2020 -- Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news